Lundbeck acquires phase I-ready candidate from South Korean firm
Lundbeck has gained exclusive rights to biotherapy candidate APB-A1 from Aprilbio. The deal may cost up to USD 448m, and Lundbeck sees potential for the drug in several neurological indications.
by Elizabeth Mønsted-johansen, translated by catherine brett
Danish pharmaceutical giant Lundbeck has acquired exclusive rights to a biotherapy candidate for treating neurological diseases from Aprilbio, in a deal that may cost up to USD 448m.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Lundbeck CEO considers stepping up marketing of Vyepti
For subscribers
Lundbeck silent on shutdown of Indian operations
For subscribers
.jpg&w=384&q=75)
